The Value of Neuropsychology in the Era of Biomarkers for Alzheimer’s Disease

Thursday, June 7, 2012

10:00 AM Pacific / 11:00 AM Mountain / 12:00 PM Central / 1:00 PM Eastern

Presented by MindAlert


Register Now

With the recent publications of the NIA-Alzheimer’s Association workgroups on revising the criteria for diagnosis of dementia due to Alzheimer’s disease, it is clear we are entering an era increasingly focused on the role of biomarkers in disease detection, diagnosis, and predicting clinical outcome.  In this seminar we will review evidence of the relative value of genetic, imaging, and CSF markers in the early detection and diagnosis of AD.  We will present evidence that neuropsychological assessment provides a central and non-interchangeable role in diagnosing AD, and that cognitive measures are among the best predictors of the initial symptomatic stages of an evolving dementia. 

Participants in this web seminar will:

  • Be able to describe three classes of biomarkers for Alzheimer’s disease
  • Learn the relative value of biomarkers and neuropsychological assessment to diagnosis of AD
  • Examine their roles in prediction of progression to dementia
  • Earn one hour of  *free* continuing education credit by attending the event and completing a CEU survey


Dr. Mark Bondi is a Professor of Psychiatry at the University of California San Diego and Director of the Neuropsychological Assessment Unit at the VA San Diego Healthcare System.  He is a Fellow of the American Psychological Association and the National Academy of Neuropsychology, and is Board Certified in Clinical Neuropsychology by the American Board of Professional Psychology.  His research centers on the cognitive and brain changes of individuals at risk for dementia, and he has published more than 120 articles and book chapters.